N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug
Kindling model
Valproic Acid
Broad spectrum
ED50
DOI:
10.1007/s13311-019-00773-w
Publication Date:
2019-09-04T17:02:58Z
AUTHORS (17)
ABSTRACT
In our recent studies, we identified compound N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) as a broad-spectrum hybrid anticonvulsant which showed potent protection across the most important animal acute seizure models such maximal electroshock (MES) test, subcutaneous pentylenetetrazole (s.c. PTZ) and 6-Hz (32 mA) test in mice. Therefore, AS-1 may be recognized candidate for new effective different types of human epilepsy with favorable safety margin profile determined rotarod aim further pharmacological evaluation AS-1, current study, examined its activity (44 is known model drug-resistant epilepsy. Furthermore, also antiseizure kindling induced by repeated injection (PTZ) As result, revealed relatively well delayed progression PTZ mice at doses 15 mg/kg, 30 60 mg/kg. Importantly, isobolographic analysis that combination valproic acid (VPA) fixed ratio 1:1 displayed supra-additive (synergistic) interaction against PTZ-induced seizures Thus, potentially used an add-on therapy VPA. Moreover, incubation zebrafish larvae substantially decreased number, cumulative but not mean duration epileptiform-like events electroencephalographic assay. Finally, vitro ADME-Tox studies characterized very good permeability parallel artificial membrane assay excellent metabolic stability on liver microsomes (HLMs), no significant influence CYP3A4/CYP2D6 activity, moderate inhibition CYP2C9 concentration 10 μM, hepatotoxic properties HepG2 cells (concentration μM).
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (79)
CITATIONS (20)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....